H. Lee Moffitt Cancer Center and Research Institute
The purpose of the study is to test a treatment strategy with currently approved drugs to see if it is practical to administer the available drugs in a new way that researchers hope could be more effective in treating metastatic breast cancer.
Inclusion Criteria: * Female patients 18 years or older * Histologically or cytologically confirmed diagnosis of hormone positive HER2 negative metastatic breast cancer per ASCO/CAP criteria (Allison et al, 2020, Wolff et al, 2018), with diagnosis established through either a breast/axillary biopsy or biopsy of a metastatic lesion. * Hormone positive MBC previously treated with endocrine therapy with either an aromatase inhibitor or Tamoxifen (alone or in combination with a CDK4/6 inhibitor). * Elevated breast tumor markers which may include cancer antigen 15-3 (CA 15-3) levels above the inst…
75 mg/m2 once every 21 days for 4 cycles
600 mg/m2 once every 21 days for 4 cycles
5.4 mg/kg once every 21 days for 5 cycles
10 mg/kg on days 1 and 8 cycled every 21 days for 5 cycles
1000 mg/m2 orally twice daily for 14 days cycled every 21 days for 5 cycles
500 mg intramuscular (IM) on days 1, 15 and 28 of the first cycle followed by every 28 days for a total of 4 cycles
600 mg orally daily 21 days on, 7 days off
150 mg by mouth twice daily
Arctuva estimate
Verify or correct the compensation shown for this listing.